Body Weight Changes Associated With Insulin Therapy : A retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled Phase III trials  

Oleh:

Hollander, Priscilla A. ; Krasner, Alan ; Klioze, Sol ; Schwartz, Pamela ; Duggan, William T.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Diabetes Care vol. 30 no. 10 (Oct. 2007), page 2508.
Topik: SC; subcutaneous

Ketersediaan

Perpustakaan FK Nomor Panggil: D05.K.2007.04 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Weight gain is commonly seen when patients are started on subcutaneous (SC) insulin. In the UK Prospective Diabetes Study, those assigned insulin gained 4 kg more than those assigned conventional therapy at 10 years (1). Given that the majority of patients with type 2 diabetes are overweight or obese (2,3), additional weight gain is clearly a concern. Furthermore, while patients with type 1 diabetes were historically often underweight, the greater use of an intensified treatment approach to achieve the benefits of improved glycemic control is associated with greater weight gain than conventional treatment (4). Fear of weight gain, along with factors such as reluctance to self-inject and fear of hypoglycemia, is a frequent deterrent to initiating insulin therapy and has been linked to reduced treatment adherence in patients with both type 1 and type 2 diabetes (5). In type 2 diabetes, the ß-cell dysfunction that leads to impaired insulin secretion is progressive, and eventually patients will require a treatment strategy that includes insulin either alone or with oral agents (6). The aim of this pooled analysis was to compare weight changes in a large population of adult patients with type 1 or type 2 diabetes receiving a regimen involving inhaled human insulin (Exubera [rDNA origin] Inhalation Powder) versus an SC insulin–only regimen......

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali